Sarat Sethi, a Managing Partner at Douglas C. Lane & Associates, is buying shares of Stryker (SYK), a medical technology giant, believing it’s trading at a significant discount. The company, a leader in orthopedic implants, surgical equipment, and robotic systems, has faced recent pressure due to a cyberattack and potential healthcare funding cuts.
Despite these temporary headwinds, Sethi highlights Stryker’s strong market positions, consistent growth, and promising expansion in robotic-assisted surgery. The stock’s current valuation, approximately 23% below its 52-week high, presents an attractive opportunity for long-term investors.
Stryker Stock: A Medical Tech Giant Trading at a Discount, Analyst Says
By Sarat Sethi
Stryker, a global leader in medical technology, presents a compelling investment opportunity, trading at a significant discount to its historical valuation, according to analyst Sarat Sethi, Managing Partner and Portfolio Manager at Douglas C. Lane & Associates. Sethi not only holds the stock personally and for his family but also identifies it as one of his firm's top picks.
Company Overview
Founded in 1941 and based in Portage, Michigan, Stryker has established itself as a powerhouse in the medical device industry. The company generates over $25 billion in annual revenue, serving more than 150 million patients worldwide. Its extensive product portfolio includes surgical implants, instruments, and advanced robotic systems used in a wide range of surgical procedures.
Key Strengths and Market Position
- Market Leadership: Stryker holds top positions in virtually all of its key markets, demonstrating a strong competitive advantage.
- Consistent Growth: The company has consistently outpaced the broader medical technology industry in terms of growth.
- Robotic-Assisted Surgery: Stryker's significant investment and presence in robotic-assisted surgery offer a substantial avenue for future expansion.
Recent Challenges and Leadership Transition
Despite its strong fundamentals, Stryker's stock has faced headwinds recently. These include a cyberattack earlier in the year and concerns about potential government healthcare funding cuts impacting demand for medical procedures. However, Sethi views these challenges as temporary and is optimistic about the company's leadership transition. On October 6th, it was announced that Spencer Stiles, a long-serving veteran with 27 years at the company, will succeed Kevin Lobo as CEO next year, with Lobo moving to the role of Executive Chairman. Stiles is well-positioned to continue Stryker's legacy of success.
Reasons for Investment
A Leader with a Competitive Moat
Stryker's market dominance is attributed to its unique operational structure. Although it reports two main business segments, the company is strategically organized into 22 specialized businesses, each responsible for its financial performance. This decentralized approach allows for focused market strategies while leveraging the resources of a global leader. Furthermore, Stryker's robust acquisition strategy, with approximately 60 acquisitions in the past decade, has broadened its product offerings and deepened its established relationships with hospitals, creating a formidable barrier to entry for competitors.
Strong Track Record and Future Growth Potential
Over the last five years, Stryker has achieved impressive organic revenue growth of around 10% annually, significantly outpacing the market. Adjusted earnings per share have seen consistent annual increases of 12-13%, accompanied by improvements in profitability, with adjusted operating margins reaching approximately 26% last year. Management anticipates further margin expansion. Sethi believes this growth trajectory is sustainable, with Stryker targeting high-end industry growth through 2028, driven by new product introductions and expansion into rapidly growing business areas.
Robotics as a Growth Engine
Sethi is particularly enthusiastic about Stryker's position in robotic-assisted surgery. The company's Mako robotic system enhances surgical planning and execution, especially in joint replacement procedures, offering greater precision. As hospitals increasingly adopt such technologies to improve patient outcomes, Stryker's established presence in this market is expected to drive significant growth. Broader demographic trends, such as an aging population boosting demand for joint replacements and the shift of surgeries to outpatient centers, further position Stryker to benefit.
Attractive Valuation
Currently trading around $304 per share, Stryker's stock is approximately 23% below its 52-week high of $392.55. This valuation presents an attractive entry point, as the stock trades at a discount compared to its historical forward earnings multiple of 24-25 times. Sethi believes that as operational issues, such as the impact of the cyberattack and supply chain disruptions, resolve, the company's growth could accelerate, leading to a potential recovery in its valuation multiple.
Risks and Outlook
The primary risks identified include prolonged operational disruptions and adverse changes in government healthcare funding that could affect procedure volumes and profitability. However, Sethi concludes that for long-term investors, Stryker offers a compelling opportunity to capitalize on its significant growth potential, particularly in the burgeoning robotic-assisted surgery market, while the stock remains attractively priced.
